Boston Scientific Corporation $BSX Shares Acquired by Atlatl Advisers LLC

Atlatl Advisers LLC increased its holdings in Boston Scientific Corporation (NYSE:BSX) by 4.2% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 6,313 shares of the medical equipment provider’s stock after acquiring an additional 254 shares during the quarter. Atlatl Advisers LLC’s holdings in Boston Scientific were worth $678,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of BSX. Brighton Jones LLC lifted its stake in shares of Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after acquiring an additional 226 shares in the last quarter. GAMMA Investing LLC raised its stake in Boston Scientific by 17.2% during the first quarter. GAMMA Investing LLC now owns 25,554 shares of the medical equipment provider’s stock valued at $2,578,000 after buying an additional 3,745 shares in the last quarter. Spire Wealth Management raised its stake in Boston Scientific by 15.9% during the first quarter. Spire Wealth Management now owns 10,630 shares of the medical equipment provider’s stock valued at $1,072,000 after buying an additional 1,456 shares in the last quarter. Golden State Wealth Management LLC raised its stake in Boston Scientific by 37.0% during the first quarter. Golden State Wealth Management LLC now owns 1,674 shares of the medical equipment provider’s stock valued at $169,000 after buying an additional 452 shares in the last quarter. Finally, Perigon Wealth Management LLC raised its stake in Boston Scientific by 7.9% during the first quarter. Perigon Wealth Management LLC now owns 13,532 shares of the medical equipment provider’s stock valued at $1,365,000 after buying an additional 996 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the sale, the executive vice president directly owned 23,600 shares in the company, valued at $2,469,268. This trade represents a 42.32% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $98.47, for a total value of $4,923,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares in the company, valued at approximately $17,561,336.74. This represents a 21.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 170,214 shares of company stock worth $17,548,337 in the last three months. 0.50% of the stock is owned by company insiders.

Boston Scientific Trading Down 1.3%

Shares of NYSE BSX opened at $101.08 on Friday. The company has a market cap of $149.78 billion, a price-to-earnings ratio of 54.06, a price-to-earnings-growth ratio of 2.34 and a beta of 0.61. Boston Scientific Corporation has a 12-month low of $80.64 and a 12-month high of $109.50. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The stock’s 50 day simple moving average is $101.14 and its 200 day simple moving average is $102.08.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.71 by $0.04. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The firm had revenue of $5.07 billion for the quarter, compared to analysts’ expectations of $4.97 billion. During the same period last year, the firm earned $0.63 EPS. The firm’s revenue was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Equities research analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Needham & Company LLC restated a “buy” rating and set a $121.00 price objective on shares of Boston Scientific in a research note on Friday, October 17th. Wall Street Zen upgraded Boston Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, October 11th. Leerink Partners upped their price objective on Boston Scientific from $127.00 to $128.00 and gave the company an “outperform” rating in a research note on Wednesday, October 1st. BTIG Research restated a “buy” rating and set a $132.00 price objective on shares of Boston Scientific in a research note on Wednesday. Finally, The Goldman Sachs Group reissued a “buy” rating and issued a $124.00 price target on shares of Boston Scientific in a report on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, Boston Scientific presently has an average rating of “Buy” and an average price target of $123.77.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.